Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Scher
    Scher
  2. Morris
    Morris
  3. Danila
    Danila
  4. Heller
    Heller
  5. Herr
    Herr
  6. Reuter
    Reuter
  7. Fleisher
    Fleisher
  8. Rathkopf
    Rathkopf
  9. Scardino
    Scardino
  10. Slovin
    Slovin

Groups

  1. Department of Medicine (119)
  2. Genitourinary Oncology Service (119)
  3. Solid Tumor Oncology Division (119)
  4. Surgery (22)
  5. Urology (22)
  6. Epidemiology and Biostatistics (19)
  7. Biostatistics Service (17)
  8. Department of Pathology and Laboratory Medicine (16)
  9. Radiology, Department of (12)
  10. Sloan Kettering Institute Faculty (12)
Search Within
  1. "Howard Scher"
Formats
  1. Journal Article (109)
  2. Meeting Abstract (4)
  3. Conference Paper (3)
  4. Editorial (2)
  5. Review (1)
Groups
  1. Department of Medicine (119)
  2. Genitourinary Oncology Service (119)
  3. Solid Tumor Oncology Division (119)
  4. Surgery (22)
  5. Urology (22)
  6. Epidemiology and Biostatistics (19)

More Groups

People
  1. Howard Scher (119)
  2. Michael Morris (19)
  3. Dana Rathkopf (13)
  4. Daniel Danila (12)
  5. William Kelly (12)
  6. Glenn Heller (11)

More People

Years
  1. 2025 (1)
  2. 2023 (4)
  3. 2022 (5)
  4. 2021 (1)
  5. 2020 (5)
  6. 2019 (1)

More Years

Publications
  1. Journal of Urology (36)
  2. European Urology (35)
  3. Urology (21)
  4. Lancet Oncology (14)
  5. American Journal of Pathology (2)
  6. Critical Reviews in Oncology/Hematology (2)

More Publications

Results (119)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer
    Journal Article

    Higano, C. S.; Beer, T. M.; Taplin, M. E.; Efstathiou, E.; Hirmand, M.; Forer, D.; Scher, H. I.
    European Urology (2015)

    Fulltext@MSK | Save
  • Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: Post hoc analysis of study COU-AA-302
    Journal Article

    Saad, F.; Shore, N.; Van Poppel, H.; Rathkopf, D. E.; Smith, M. R.; de Bono, J. S.; Logothetis, C. J.; De Souza, P.; Fizazi, K.; Mulders, P. F. A.; more...
    European Urology (2015)

    Fulltext@MSK | Save
  • Observed advantages of the STAMPEDE study design
    Journal Article

    Scher, H. I.
    European Urology (2015)

    Fulltext@MSK | Save
  • Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): A double-blind, multicentre, phase 3, randomised, placebo-controlled trial
    Journal Article

    Saad, F.; Fizazi, K.; Jinga, V.; Efstathiou, E.; Fong, P. C.; Hart, L. L.; Jones, R.; McDermott, R.; Wirth, M.; Suzuki, K.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: Exploratory analysis from COU-AA-301
    Journal Article

    Montgomery, B.; Kheoh, T.; Molina, A.; Li, J.; Bellmunt, J.; Tran, N.; Loriot, Y.; Efstathiou, E.; Ryan, C. J.; Scher, H. I.; more...
    European Urology (2015)

    Fulltext@MSK | Save
  • Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort
    Journal Article

    Basch, E.; Autio, K. A.; Smith, M. R.; Bennett, A. V.; Weitzman, A. L.; Scheffold, C.; Sweeney, C.; Rathkopf, D. E.; Smith, D. C.; George, D. J.; more...
    European Urology (2015)

    Fulltext@MSK | Save
  • Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial
    Journal Article

    Saad, F.; de Bono, J.; Shore, N.; Fizazi, K.; Loriot, Y.; Hirmand, M.; Franks, B.; Haas, G. P.; Scher, H. I.
    European Urology (2014)

    Fulltext@MSK | Save
  • Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial
    Journal Article

    Fizazi, K.; Scher, H. I.; Miller, K.; Basch, E.; Sternberg, C. N.; Cella, D.; Forer, D.; Hirmand, M.; de Bono, J. S.
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
    Journal Article

    Rathkopf, D. E.; Smith, M. R.; de Bono, J. S.; Logothetis, C. J.; Shore, N. D.; De Souza, P.; Fizazi, K.; Mulders, P. F. A.; Mainwaring, P.; Hainsworth, J. D.; more...
    European Urology (2014)

    Fulltext@MSK | Save
  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial
    Journal Article

    Kwon, E. D.; Drake, C. G.; Scher, H. I.; Fizazi, K.; Bossi, A.; Van Den Eertwegh, A. J. M.; Krainer, M.; Houede, N.; Santos, R.; Mahammedi, H.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save